吉西他滨联合顺铂一线治疗晚期triple-negative乳腺癌41例临床研究

目的：观察吉西他滨联合顺铂（GP）一线治疗triple-negative（ER、PR、HER-2均阴性）晚期转移性乳腺癌的疾病进展时间、疗效和安全性。方法：2008年1月-2010年4月共41例经免疫组化检查证实为tri-ple-negative的晚期乳腺癌初治患者参与研究。患者接受吉西他滨联合顺铂方案治疗：吉西他滨1000mg/m2,静脉滴注30min,d1、d8;顺铂25mg/m2静脉滴注d1-3天,21天重复。结果：全组41例共完成160个周期的治疗,中位数4个周期,范围2-6个周期,均可评价疗效。完全缓解（CR）2例（4.88%）,部分缓解（PR）21例（51.22%）,病情稳定（SD）7例（17.07%）,病情进展（PD）11例（26.83%）。临床总缓解率（CR＋PR）56.10%;疾病控制率（CR＋PR＋SD）73.17%;中位疾病进展时间（mTTP）8.4个月,1年生存率65.85%。不良反应主要为Ⅰ-Ⅱ度骨髓抑制、末梢神经毒性、胃肠道反应、轻度肝功能损伤等。结论：吉西他滨联合顺铂一线治疗triple-negative晚期转移性乳腺癌患者,初步观察疗效较好,不良反应可耐受,值得进一步研究。

The study of gemcitable combined with cisplatin in the first line treatment of forty-one patints with triple-negative metastatic breast cancer

Objective：To observe the therapeutic effect and drug tolerance of gemcitable combined with cisplatin in the first line treatment of triple-negative metastatic breast cancer.Methods： Forty-one patints with immunohistochemical proved tiple-negative metastatic breast cancer were enrolled.The patients received gemcitable 1000mg/m2（on day 1 and day 8）and cisplatin 25mg/m2（from day 1 to 3）.Results：A total of 160 cycles were given to 41 patients（median 4;range 2-6 cycles）.The treatment response was evaluable in all patients of 41 patients.2 received complete remission（CR）,21 partial remission（CR）,7 stable diease（SD）,11 progressive diease（PD）.Response rate（CR＋PR） was 56.10%.Ⅰ-Ⅱness control rate（CR＋PR＋SD） was 73.17%;The median time to progress（mTTP） was 8.4 months.The median 1-year survival rate was 65.85%.The major adverse events were grade Ⅰ-Ⅱ myelosuppression,peripheral neurologic,nausea and vomiting,some patients had and hepatic dysfunction.Conclusion：The combination of gemcitable and cisplatin is an effective and well tolerated regimen for the patients with triple-negative metastatic breast cancer.